



PATENT  
Customer No. 23630  
Attorney Docket No. 068911-0076


**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Eric Kuhrts  
Serial No.: 10/008,778  
Filed: November 13, 2001  
Title: Novel Anti-Inflammatory Cyclooxygenase Inhibitors  
Docket: 068911-0076  
Confirmation No: 4731  
Art Unit: 1655  
Examiner: Michael V. Meller

**CERTIFICATE OF MAILING OR TRANSMISSION**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service via First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, or filed via EFS-Web to the USPTO, on the date indicated below.

Date: August 19, 2008

  
Jacqueline Andreu

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)**

Applicant and his attorneys are aware of the following publications and information, listed on the attached Form PTO-1449 Form, and in accordance with 37 C.F.R. §§ 1.56 and 1.97(b) hereby submit these publications for the Examiner's consideration. According to the United States Patent and Trademark Office OG Notices: 05 August 2003, copies of the cited U.S. patents and U.S. patent application publications are waived and not submitted with this Statement. Enclosed are copies of foreign patent references cited as B1-B21, and other cited art as C1-C66.

This Statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicant understands that the Examiner will make an independent evaluation of the cited publications.

U.S. Application Serial No. 10/008,778  
Eric Kuhrts  
Filing Date: November 13, 2001

If the Examiner applies any of the documents as prior art against any claim in the application and applicant determines that the cited document does not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents. Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

No costs are believed to be due with the filing of this disclosure. However, please charge any necessary fee to our Deposit Account No. 50-1133.

Respectfully submitted,

McDermott Will & Emery, LLP.

A handwritten signature in black ink, appearing to read 'Atabak Royae', is written over a horizontal line.

Dated: August 19, 2008

Atabak R. Royae, Reg. No. 59,037  
McDERMOTT, WILL & EMERY, LLP.  
28 State Street  
Boston, Massachusetts 02109-1775  
Tel. (617) 535-4108  
Fax: (617) 535-3800



**PATENT**  
**Customer No. 23630**  
**Attorney Docket No. 068911-0076**


**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Eric Kuhrts  
Serial No.: 10/008,778  
Filed: November 13, 2001  
Title: Novel Anti-Inflammatory Cyclooxygenase Inhibitors  
Docket: 068911-0076  
Confirmation No: 4731  
Art Unit: 1655  
Examiner: Michael V. Meller

**CERTIFICATE OF MAILING OR TRANSMISSION**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service via First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, or filed via EFS-Web to the USPTO, on the date indicated below.

Date: August 19, 2008

  
Jacqueline Andreu

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**


Enclosed for filing in connection with the above-referenced patent application are the following documents:

- 1) Information Disclosure Statement (2 pages)
- 2) Information Disclosure Statement by Applicant (Form 1449) (5 pages);
- 3) Cited references as B1-B21 and C1-C66; and
- 4) Return receipt postcard.

No costs are believed to be due with the filing of this Information Disclosure Statement. However, the Commissioner is authorized to charge any necessary fee to our Deposit Account No. 50-1133.

Respectfully submitted,

McDermott Will & Emery LLP



Atabak R. Royae, Reg. No.: 59,037  
McDermott Will & Emery LLP  
28 State Street  
Boston, MA 02109-1775  
Telephone: (617) 535-4108  
Facsimile: (617) 535-3800

Date: August 19, 2008